Eliot A. Brinton

Affiliation: Utah Lipid Center, Salt Lake City, UT
Institution: Utah Lipid Center
ORCID: 0000-0002-9807-4010
External IDs: ResearchGate: Eliot_Brinton | Google Scholar: Eliot A. Brinton
Email: eliot.brinton@utahlipidcenter.com
Works: 100, Cited by: 5000, H-index: 50
Dr. Eliot A. Brinton is a renowned expert in Clinical Lipidology, Metabolism, Endocrinology, and Nutrition. He has a distinguished career with significant contributions to the field and has been recognized with prestigious scientific awards. Currently serving as the President of the Utah Lipid Center in Salt Lake City.

Education

  • M.D., The University of Utah School of Medicine (-)
  • Internal Medicine Residency, Duke University (-)
  • Fellowship in Metabolism, Endocrinology and Nutrition, The University of Washington (-)

Research Interests

Keywords:
Clinical Lipidology Metabolism Endocrinology Nutrition
Topics:
Lipidology Metabolism Endocrinology Nutrition

Professional Links

Selected Publications

Omega-3 reduces cardiovascular risk
Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
PubMed DOI
Omega-3 benefits for smokers' heart health
Miller M, Bhatt DL, Steg PG, Brinton EA, Jacobson TA, et al. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. Eur Heart J Cardiovasc Pharmacother. 2023;9:129. doi:10.1093/ehjcvp/pvac045
PubMed DOI
Eicosapentaenoic acid reduces heart attack risk
Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, et al. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024;83:1529. doi:10.1016/j.jacc.2024.02.016
PubMed DOI

Related Products